Join the inaugural episode of the new Rare Conversations event series in 2022, aimed at powering the next decade of rare disease innovation in Europe.
The first episode will be focused on game-changing opportunities for the R&D community to address existing challenges in rare diseases. The aim is to understand what is the basis needed to build the foundations for the future innovative rare disease ecosystem.
The event, organized by Alexion, AstraZeneca Rare Disease, in cooperation with the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), will revolve around discussions on how the revision of the OMP Regulation can create a space for opportunities for scientific progress.
Block your calendar for 6th April from 14.00 – 15.15 CET. More information and the registration link will be shared with you shortly.
About “Rare Conversations”
Rare Conversations is an event series organized by Alexion to educate on rare diseases and facilitate multi-stakeholder exchange, tackling timely topics of interest such as the revision of the OMP Regulation. Rare Conversations aims to unite and engage the rare disease community, including key stakeholders in Brussels and EU Member States. Since its inception in December 2020, four Rare Conversations have taken place, each in cooperation with a different partner and focused on specific topics, such as COVID and rare diseases, the specificities of research in rare disease, and EU and national value assessment for orphan drugs. People with rare diseases always stay at the centre of our activities and are part of every event.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.